Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd. Janik JE, et al. Among authors: miller ll. J Natl Cancer Inst. 1996 Jan 3;88(1):44-9. doi: 10.1093/jnci/88.1.44. J Natl Cancer Inst. 1996. PMID: 8847725 Clinical Trial.
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Janik JE, Miller LL, Korn EL, Stevens D, Curti BD, Smith JW 2nd, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL. Janik JE, et al. Among authors: miller ll. Blood. 2001 Apr 1;97(7):1942-6. doi: 10.1182/blood.v97.7.1942. Blood. 2001. PMID: 11264156 Free article. Clinical Trial.
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW 2nd, Urba WJ, Donegan SE, Watson TM, Longo DL. Miller LL, et al. Blood. 1999 May 15;93(10):3250-8. Blood. 1999. PMID: 10233876 Free article. Clinical Trial.
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE, Miller LL, Kopp WC, Taub DD, Dawson H, Stevens D, Kostboth P, Curti BD, Conlon KC, Dunn BK, Donegan SE, Ullrich R, Alvord WG, Gause BL, Longo DL. Janik JE, et al. Among authors: miller ll. Clin Immunol. 1999 Dec;93(3):209-21. doi: 10.1006/clim.1999.4778. Clin Immunol. 1999. PMID: 10600331 Clinical Trial.
Phase II study of adozelesin in untreated metastatic breast cancer.
Cristofanilli M, Bryan WJ, Miller LL, Chang AY, Gradishar WJ, Kufe DW, Hortobagyi GN. Cristofanilli M, et al. Among authors: miller ll. Anticancer Drugs. 1998 Oct;9(9):779-82. doi: 10.1097/00001813-199810000-00006. Anticancer Drugs. 1998. PMID: 9840723 Clinical Trial.
414 results